Clinical trial
Study on Transarterial Chemoembolization Combined With Sorafenib in Chinese Patients With Unresectable Hepatocellular Carcinoma (SUCCESS)
NCT01839630 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study on Transarterial Chemoembolization Combined With Sorafenib in Chinese Patients With Unresectable Hepatocellular Carcinoma (SUCCESS)
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 30, 2013
- Completion date
- December 29, 2016
- Enrollment
- 302 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.